the controversy.

every ingredient in this line has been called fake, dangerous, overhyped, or some combination of the three by someone with a camera and an opinion.

some of those criticisms are right. most are partial. a few are wrong on the science.

i'm not going to pretend the arguments don't exist. i'm going to host them. for every ingredient i use, here are the five loudest things people say about it -- what's true in the criticism, and where the studies actually land.

if i thought a study disqualified an ingredient, it wouldn't be in the bottle. but i'd rather you see the argument than google it later and feel lied to.

-- marty

ashwagandha

KSM-66 root extract, 600 mg/day

used in: marty-02

KSM-66 is a milk-and-water-extracted root-only standardized extract of Withania somnifera, dosed at 600 mg/day (300 mg twice daily) for stress, sleep, and androgen support. the most clinically studied branded ashwagandha and the form Health Canada has approved for the claim "helps promote healthy testosterone production in males."

it's also one of the most-debunked supplements on the internet right now. here are the five things people say about it.

“ashwagandha can cause emotional blunting and flat affect similar to SSRIs.”

WHAT’S RIGHT ABOUT IT.

this is the loudest TikTok/Reddit complaint, and it is not entirely fabricated. preclinical work shows chronic ashwagandha modulates serotonergic signaling in ways analogous to SSRIs -- Bhattacharya et al. (Phytotherapy Research 1995) showed downregulation of 5-HT1A and upregulation of 5-HT2 receptor sensitivity after chronic dosing, the same pharmacology blamed for emotional blunting on SSRIs. no published RCTs have primarily measured anhedonia or emotional reactivity, so the patient experience is not formally falsified.

WHERE IT LANDS IN THE LITERATURE.

no RCT has reported emotional blunting as an adverse event at the 600 mg dose. the largest pooled adverse-event analysis -- Fatima K et al. (Human Psychopharmacology 2024; 12 RCTs, doses 150-600 mg, 4-12 weeks) -- found only minor, transient AEs (somnolence, GI upset) and no signal for emotional flattening. Akhgarjand C et al. (Phytotherapy Research 2022; 12 RCTs, n=1002) reported significant reductions in anxiety (SMD -1.55) and stress (SMD -1.75) with no offsetting blunting signal.

-- citation --

Bhattacharya SK et al. Phytother Res 1995; 9: 110-113.

Fatima K et al. Hum Psychopharmacol 2024; 39(6): e2911.

Akhgarjand C et al. Phytother Res 2022; 36(11): 4115-4124.

marty · by therma

“the testosterone evidence is built on small, industry-adjacent trials.”

WHAT’S RIGHT ABOUT IT.

the foundational testosterone RCTs are small and many are sponsored by or use product supplied by Ixoreal Biomed (KSM-66's manufacturer). Ambiye VR et al. (2013) used n=46 oligospermic men. Wankhede S et al. (2015) used n=57 healthy men. Lopresti AL et al. (2019) used n=57. none has been replicated in a multi-center, non-industry-sponsored trial of >200 men.

WHERE IT LANDS IN THE LITERATURE.

the effect is consistent across small replications. Smith SJ et al. (J Diet Suppl 2023) meta-analysis pooled four trials (n~250) and found a modest but significant total testosterone increase (~14-22%) versus placebo at 600 mg/day for 8-16 weeks. the honest framing: real signal, modest magnitude (~50-100 ng/dL absolute), strongest in stressed/subfertile men, weakest in young eugonadal men. not testosterone replacement therapy.

-- citation --

Ambiye VR et al. Evid Based Complement Altern Med 2013; 2013: 571420 (n=46, +17% T).

Wankhede S et al. J Int Soc Sports Nutr 2015; 12: 43 (n=57, +96 vs +18 ng/dL, p=0.004).

Lopresti AL et al. Am J Mens Health 2019; 13(2).

marty · by therma

“there are real, published case reports of ashwagandha-induced liver injury.”

WHAT’S RIGHT ABOUT IT.

conceded fully. the NIH LiverTox database (updated December 2024) classifies ashwagandha as a "probable" cause of clinically apparent liver injury (likelihood score C). documented cases include Philips CA et al. (Hepatology Communications 2023; 8 single-ingredient cases from India, cholestatic predominant); Lubarska M et al. (2023; RUCAM 6, probable); and Almuzghi F et al. (Cureus 2024; RUCAM 7, hepatocellular injury after only 2 days). the Netherlands Pharmacovigilance Centre Lareb has logged multiple reports. the Iceland DILI registry first flagged this in 2020.

WHERE IT LANDS IN THE LITERATURE.

true risk, very low absolute incidence given prevalence of use. Bokan G et al. (Pharmaceuticals 2023) reviewed published cases worldwide and concluded the pattern is idiosyncratic, latency typically 2-12 weeks, mostly hepatocellular or mixed, generally reversible on cessation. no specific HLA risk allele has yet been confirmed. mechanism is hypothesized to involve withanolide-driven hepatic glutathione depletion. anyone with baseline liver disease, on hepatotoxic medications, or with unexplained ALT/AST elevations should avoid ashwagandha; stop immediately for jaundice, RUQ pain, or unexplained fatigue.

-- citation --

Bjornsson HK et al. Liver Int 2020; 40(4): 825-829 (Iceland, 5 cases).

Philips CA et al. Hepatol Commun 2023; 7(10): e0270.

LiverTox: NIH/NIDDK 2024 (NBK548536).

Almuzghi F et al. Cureus 2024; 16(10): e71576.

marty · by therma

“ayurvedic "tradition" is not evidence.”

WHAT’S RIGHT ABOUT IT.

correct as stated. tradition of use is not a clinical endpoint. several traditional Ayurvedic preparations have been adulterated with heavy metals -- Saper RB et al. (JAMA 2008) found ~21% of US-marketed Ayurvedic products contained detectable lead, mercury, or arsenic.

WHERE IT LANDS IN THE LITERATURE.

MARTY's case for ashwagandha rests on RCT/meta-analytic evidence, not tradition. the current evidence base: Bachour G et al. (BJPsych Open 2025; 15 RCTs, n=873) showing significant cortisol, stress, and anxiety reductions; Cheah KL et al. (PLOS ONE 2021; 5 RCTs, n=400; SMD -0.59 for sleep). tradition motivated the research; it is not the research.

-- citation --

Saper RB et al. JAMA 2008; 300(8): 915-923.

Cheah KL et al. PLOS ONE 2021; 16(9): e0257843.

Bachour G et al. BJPsych Open 2025.

marty · by therma

“all ashwagandha is the same -- KSM-66 is just marketing.”

WHAT’S RIGHT ABOUT IT.

there is no published head-to-head RCT comparing KSM-66 to Sensoril or to generic root powder. the argument that branding is partly commercial is reasonable.

WHERE IT LANDS IN THE LITERATURE.

the Frontiers in Nutrition AI-driven safety review (2025) found that root-only preparations have a meaningfully better predicted safety profile than leaf or whole-plant preparations -- relevant because most published DILI cases involved multi-part or unstandardized products. KSM-66 is root-only, water-and-milk-extracted, standardized to >=5% withanolides, and nearly every positive RCT used either KSM-66 or Sensoril at defined withanolide content. generic ashwagandha at unknown withanolide content cannot be assumed equivalent.

-- citation --

Frontiers in Nutrition 2025 (Comprehensive safety evaluation of Withania somnifera).

Verma N et al. F1000Research 2023; 12: 335.

marty · by therma

THE BOTTOM LINE.

ashwagandha at 600 mg/day of a standardized root extract has the strongest RCT base of any adaptogen for stress and sleep, and a real but small testosterone signal in stressed men. hepatotoxicity is rare but documented and the appropriate response is awareness and stop-rules, not dismissal. people with liver disease, on hepatotoxic drugs, or with mood disorders being treated with serotonergic agents should not take it without clinical oversight.

saffron

affron, >=3.5% lepticrosalides, 28 mg/day

used in: marty-03, marty-05

affron is a Spanish-grown Crocus sativus stigma extract standardized to >=3.5% Lepticrosalides (a complex of crocins, picrocrocin, and safranal), produced by Pharmactive Biotech. used at 28 mg/day for low mood, perceived stress, and sleep quality.

it's also a frequent target of 'expensive placebo' criticism. here are the five things people say about it.

“saffron is an expensive placebo dressed up with antidepressant comparisons.”

WHAT’S RIGHT ABOUT IT.

saffron trials are typically small, short, and frequently conducted in single Iranian centers under the same research groups (Akhondzadeh and colleagues), which raises legitimate publication-bias concerns. Hausenblas HA et al. (Journal of Integrative Medicine 2013) explicitly noted these limitations in their meta-analysis of five trials.

WHERE IT LANDS IN THE LITERATURE.

replication has now extended well beyond Iran. Shafiee A et al. (Nutrition Reviews 2024) and Yang X et al. (Neuropsychiatr Dis Treat 2018) both found statistically significant superiority over placebo and non-inferiority to fluoxetine 20-40 mg. the 2025 Journal of Nutrition trial of affron specifically (Lopresti et al., n=202, 12 weeks, 28 mg/day) -- the largest and longest trial of this branded extract -- showed clinically meaningful reductions in depressive symptoms (72% response vs. 54% placebo). the placebo claim is no longer defensible at meta-analytic level, though "as good as fluoxetine" should be read as "as good as fluoxetine in mild-to-moderate depression in selected populations."

-- citation --

Hausenblas HA et al. J Integr Med 2013; 11(6): 377-383.

Yang X et al. Neuropsychiatr Dis Treat 2018; 14: 1297-1305.

Lopresti AL et al. J Nutr 2025 (affron 28 mg, n=202).

marty · by therma

“saffron has serotonergic activity and could cause serotonin syndrome with SSRIs, MAOIs, or tricyclics.”

WHAT’S RIGHT ABOUT IT.

mechanistically plausible and worth flagging. crocin has been shown in vitro and in animal models to inhibit monoamine oxidase A and B and to modulate serotonin reuptake. co-administration with serotonergic agents has not been formally tested for safety in adequately powered RCTs.

WHERE IT LANDS IN THE LITERATURE.

no published case reports of serotonin syndrome from saffron + SSRIs/MAOIs/tricyclics exist as of April 2026, despite hundreds of trial participants on co-medication. Kashani L et al. (Hum Psychopharmacol 2013; n=34, 30 mg/day saffron added to fluoxetine) reported no SS or hypertensive events. the conservative position -- disclosed on the label -- is to consult a clinician before combining saffron with prescription serotonergic agents, particularly MAOIs.

-- citation --

Kashani L et al. Hum Psychopharmacol 2013; 28(1): 54-60.

Hosseinzadeh H, Sadeghnia HR. J Pharm Pharm Sci 2007; 10(1): 82-93.

marty · by therma

“28 mg is below the 30 mg dose used in most studies.”

WHAT’S RIGHT ABOUT IT.

the classic Akhondzadeh-era trials used 30 mg/day, and the most cited fluoxetine-comparison trials used 30 mg/day. 28 mg is genuinely 7% lower.

WHERE IT LANDS IN THE LITERATURE.

affron specifically has been studied at 22 mg/day and 28 mg/day. Kell G et al. (Complement Ther Med 2017; affron 22 and 28 mg, n=128, 4 weeks) found significant POMS improvements at 28 mg. the 2025 Lopresti J Nutr trial (28 mg, n=202, 12 weeks) used precisely 28 mg and met primary endpoints. the 28 mg dose is within studied range for this specific extract; it would be inadequate to claim equivalence to 30 mg of an unstandardized stigma powder, but as 28 mg of standardized affron it is not a sub-therapeutic shortcut.

-- citation --

Kell G et al. Complement Ther Med 2017; 33: 58-64.

Lopresti AL et al. J Nutr 2025.

marty · by therma

“saffron is the most-adulterated spice in the world.”

WHAT’S RIGHT ABOUT IT.

documented at length in food-fraud literature. bulk saffron is routinely cut with safflower, marigold, turmeric, or dyed corn silk. heavy metals and microbial contamination are real concerns for unstandardized stigma powders.

WHERE IT LANDS IN THE LITERATURE.

standardized HPLC-quantified extracts (affron, Safr'Inside, Crocus Inside) are not equivalent to retail saffron threads and are subject to identity testing and limit-of-detection assays for crocins, safranal, and picrocrocin. this is a legitimate criticism of "saffron supplements" generically and a non-issue for HPLC-standardized branded extracts of documented provenance.

-- citation --

Moras B, Loffredo L, Rey S. Food Chemistry 2018; 257: 380-389.

marty · by therma

“most positive saffron studies are funded or seeded by the extract manufacturers.”

WHAT’S RIGHT ABOUT IT.

conceded. the affron trials are funded by Pharmactive or use Pharmactive-supplied product; Lopresti has frequently consulted for industry; many Iranian trials use locally produced saffron without disclosed independent assay. this is a real publication-bias concern.

WHERE IT LANDS IN THE LITERATURE.

industry-independent meta-analyses (Hausenblas 2013; Yang 2018; Shafiee 2024) which pool both sponsored and unsponsored data still find effect sizes well above zero, with small/zero-trim sensitivity analyses preserving significance. industry sponsorship inflates effects but does not eliminate them.

-- citation --

Shafiee A et al. Nutrition Reviews 2024 (saffron vs. SSRIs meta-analysis).

marty · by therma

THE BOTTOM LINE.

saffron at 28 mg/day of a standardized extract has surprisingly robust evidence for mild-to-moderate low mood and is generally well tolerated. the "as effective as fluoxetine" claim is overstated outside of mild/moderate depression. combine with prescription antidepressants only with clinical oversight.

magnesium glycinate

TRAACS chelate, 200-300 mg elemental

used in: marty-01, marty-04, marty-05, marty-07, marty-09

Albion's TRAACS magnesium bisglycinate chelate, dosed at 200-300 mg elemental Mg/day for sleep onset, muscle relaxation, and stress modulation. glycine is co-bonded to the magnesium ion as a dipeptide-mimicking carrier.

it's also the supplement most often called overhyped or unnecessary. here are the five things people say about it.

“all magnesium forms are basically the same -- bisglycinate is a marketing premium.”

WHAT’S RIGHT ABOUT IT.

partially true at the population level. Schuette SA et al. (JPEN 1994; n=12 ileal-resection crossover) found similar pooled absorption between magnesium diglycinate and oxide (23.5% vs. 22.8%), though chelate was significantly better in the four most malabsorptive patients.

WHERE IT LANDS IN THE LITERATURE.

where bisglycinate genuinely outperforms is GI tolerability and dose-dependent absorption at higher doses. Walker AF et al. (Magnesium Research 2003) found Mg amino-acid chelate produced higher RBC Mg than Mg oxide despite similar serum levels. bisglycinate is also less likely to cause the osmotic diarrhea that limits dose escalation with oxide and citrate. calling it "the same" understates real differences in tolerability and intracellular delivery; calling it "twice as bioavailable" overstates the effect in healthy adults.

-- citation --

Schuette SA et al. JPEN J Parenter Enteral Nutr 1994; 18(5): 430-435.

Walker AF et al. Magnes Res 2003; 16(3): 183-191.

marty · by therma

“most people get enough magnesium from food.”

WHAT’S RIGHT ABOUT IT.

the RDA is 320-420 mg. US NHANES data show 30-50% of adults are below the EAR. Moshfegh AJ et al. (USDA 2009) found 48% of Americans below the EAR. "most people" is wrong, but the population is not as deficient as supplement marketing suggests, and outright deficiency is uncommon.

WHERE IT LANDS IN THE LITERATURE.

subclinical insufficiency (low intake without overt hypomagnesemia) is associated with insomnia, leg cramps, migraine, and impaired glucose handling. Mah J, Pitre T (BMC Complementary Medicine 2021; 3 RCTs, n=151 older adults with insomnia) found magnesium reduced sleep onset latency by 17.36 minutes (95% CI -27.27 to -7.44) versus placebo. the clinical signal is most reliable in older adults and populations with confirmed lower intake.

-- citation --

Mah J, Pitre T. BMC Complement Med Ther 2021; 21: 125.

Moshfegh A et al. USDA ARS 2009.

marty · by therma

“magnesium is dangerous in kidney disease.”

WHAT’S RIGHT ABOUT IT.

fully conceded. symptomatic hypermagnesemia case reports are well documented, particularly with Mg-containing laxatives in older patients with reduced GFR. Wakai E et al. (CEN Case Reports 2019; 4 elderly patients; one died). Onishi S et al. (Cureus 2025; PD patient, 8.4 mg/dL, mechanical ventilation needed). up to 70% of magnesium is renally excreted; CKD stage 3+ patients should not take Mg supplements without nephrology oversight.

WHERE IT LANDS IN THE LITERATURE.

in healthy adults with normal renal function, 200-300 mg of elemental supplemental Mg is well below safety thresholds. the Institute of Medicine UL for supplemental Mg (above food sources) is 350 mg/day for adults, and bisglycinate is among the least likely forms to push intake above tolerance.

-- citation --

Wakai E et al. CEN Case Rep 2019; 8(1): 30-34.

Institute of Medicine. Dietary Reference Intakes for Magnesium. National Academies Press; 1997.

marty · by therma

“magnesium oxide is a fraction of the price.”

WHAT’S RIGHT ABOUT IT.

true at the unit level. Mg oxide is roughly 5-10x cheaper per mg elemental.

WHERE IT LANDS IN THE LITERATURE.

Mg oxide has 4-15% bioavailability in healthy controls (Lindberg JS et al. J Am Coll Nutr 1990), causes substantially more GI upset, and raised RBC Mg meaningfully less than chelated forms in head-to-head work. for laxative effect or short-term repletion, oxide is reasonable; for daily sleep/relaxation use it is poorly tolerated and most of what you swallow is excreted.

-- citation --

Lindberg JS, Zobitz MM, Poindexter JR, Pak CY. J Am Coll Nutr 1990; 9(1): 48-55.

marty · by therma

“there is no magnesium-glycinate-specific RCT for sleep.”

WHAT’S RIGHT ABOUT IT.

most magnesium-and-sleep RCTs used Mg oxide, citrate, or a mixed-chelate formulation -- not isolated bisglycinate. the direct evidence base for bisglycinate specifically on sleep is smaller than the marketing implies. Abbasi B et al. (J Res Med Sci 2012; n=46, elderly insomnia) used 500 mg Mg oxide.

WHERE IT LANDS IN THE LITERATURE.

glycine has independent sleep evidence at 3 g (see glycine section). bisglycinate at 200-300 mg elemental delivers approximately 1-1.5 g of glycine concomitantly, plausibly contributing additive sleep-onset benefit. the strongest interpretation: the magnesium portion has class evidence; the glycinate portion has glycine evidence; the "bisglycinate-as-sleep-aid" claim is mechanistically reasonable but not directly RCT-proven.

-- citation --

Abbasi B et al. J Res Med Sci 2012; 17(12): 1161-1169.

marty · by therma

THE BOTTOM LINE.

magnesium at 200-300 mg elemental from a chelate with good GI tolerance is one of the better-evidenced sleep-onset interventions in supplement form, with a clear contraindication in moderate-to-severe kidney disease.

sea moss

wildcrafted chondrus crispus, 1,500 mg

used in: marty-10

this is the weakest-evidence ingredient in the MARTY line, and that is worth saying out loud. Chondrus crispus is a North Atlantic red algae used at 1,500 mg/day for skin, gut, and trace-mineral support.

it's also the ingredient with the thinnest evidence base in the line. i won't pretend otherwise. here are the five things people say about it.

“sea moss is a heavy-metal sponge -- lead, cadmium, arsenic, mercury.”

WHAT’S RIGHT ABOUT IT.

conceded as a structural fact. algae bioaccumulate marine contaminants. Almela C et al. (Food Addit Contam 2002) found total arsenic up to 162 mg/kg dry weight in some seaweeds. Lavoie M et al. (Sci Rep 2023) documented elevated heavy metals in farmed New England sugar kelp. Banach JL et al. (EFSA 2020) confirmed substantial inorganic As, Cd, Pb, and Hg variability across edible seaweeds.

WHERE IT LANDS IN THE LITERATURE.

most arsenic in red seaweed is organic arsenosugars, which have substantially lower toxicity than inorganic arsenic -- Taylor V et al. (Environment International 2017) found low conversion to toxic thio-DMA in human urine. risk depends almost entirely on sourcing, lot testing, and species. Chondrus crispus specifically has lower As accumulation than brown seaweeds. the legitimate consumer demand is third-party COA showing inorganic As, Pb, Cd, and Hg below California Prop 65 limits per serving -- not "wildcrafted" marketing copy.

-- citation --

Almela C et al. J Agric Food Chem 2002; 50(4): 918-923.

Taylor V et al. Environment International 2017; 99: 358-370.

Banach JL et al. EFSA Supporting Publications 2020; 17(5).

marty · by therma

“iodine content can blow out your thyroid.”

WHAT’S RIGHT ABOUT IT.

real risk, real cases. iodine in Chondrus crispus varies 50-fold by batch and harvest site. the Tolerable Upper Intake Level for iodine in adults is 1,100 mcg/day. NIH LactMed explicitly warns that maternal seaweed consumption has caused thyroid suppression in breastfed infants. people with autoimmune thyroid disease (Hashimoto's, Graves') are particularly vulnerable.

WHERE IT LANDS IN THE LITERATURE.

risk is dose- and population-dependent. Banach et al. (EFSA 2020) modeled that even modest C. crispus intake can exceed UL when iodine content is at the high end. anyone with known thyroid disease, on levothyroxine, pregnant, or breastfeeding should not take sea moss without endocrinology input, and any product not stating mcg of iodine per serving (with batch variability bounds) is functionally unsafe.

-- citation --

NIH/NLM Drugs and Lactation Database (LactMed) NBK621050.

Leung AM, Braverman LE. Nat Rev Endocrinol 2014; 10(3): 136-142.

marty · by therma

“carrageenan in sea moss causes inflammation.”

WHAT’S RIGHT ABOUT IT.

Chondrus crispus is the classical commercial source of carrageenan, and the carrageenan-and-IBD literature is real. Borthakur A et al. (Nutr Healthy Aging 2017; n=12 UC patients in remission) found earlier disease relapse with food-grade carrageenan vs. carrageenan-free diet (p=0.046). David S et al. (Nutrients 2021) connected carrageenan to IBD pathophysiology.

WHERE IT LANDS IN THE LITERATURE.

EFSA and FDA continue to classify food-grade (non-degraded, high-MW) carrageenan as GRAS at typical dietary intakes. degraded (poligeenan) carrageenan is the inflammatory form and is not used in food. McKim JM et al. (Nutr Healthy Aging 2019) critiqued the Borthakur trial's design. people with active IBD or known carrageenan sensitivity should not take whole C. crispus; people without GI disease at 1,500 mg/day are unlikely to ingest a meaningful inflammatory load relative to processed food intake.

-- citation --

Borthakur A et al. Nutr Healthy Aging 2017; 4(2): 181-192.

David S et al. Nutrients 2021; 13(10): 3402.

McKim JM et al. Nutr Healthy Aging 2019; 5(2): 143-150.

marty · by therma

“there are no human RCTs of chondrus crispus for any of the claims people use it for.”

WHAT’S RIGHT ABOUT IT.

conceded entirely. there is no published placebo-controlled RCT of whole Chondrus crispus supplementation in humans for skin, hair, libido, thyroid, immunity, or weight. the Office of Dietary Supplements (NIH) and OPSS state explicitly there is insufficient evidence to confirm safety or efficacy. Park S-J et al. (Marine Drugs 2024) reviews chemistry and in-vitro/animal data only.

WHERE IT LANDS IN THE LITERATURE.

this is an evidence gap, not a refuted claim. MARTY 10's positioning as a mineral and prebiotic-fiber food (vitamins, iodine, dietary fiber) rather than a clinical intervention is the honest framing. specific health claims (hair growth, libido, thyroid support) are not supported by RCT evidence in C. crispus.

-- citation --

Park S-J et al. Marine Drugs 2024; 22(1): 47.

Office of Dietary Supplements/OPSS sea moss factsheet (US DoD, 2024).

marty · by therma

“"wildcrafted" is marketing -- pool-farmed sea moss is the norm and is often misrepresented.”

WHAT’S RIGHT ABOUT IT.

largely true as a market reality. most commercial Caribbean "sea moss" sold in the US is pool-cultivated Eucheuma or Kappaphycus mislabeled as Chondrus crispus. true wildcrafted C. crispus is North Atlantic, harvested from rocky shores in Maine, Atlantic Canada, Ireland, and the UK.

WHERE IT LANDS IN THE LITERATURE.

species verification by DNA barcoding or HPLC fingerprinting is the only credible answer; product labels claiming "wildcrafted Chondrus crispus" without batch-level COA or DNA verification are not defensible. this is a sourcing-transparency issue MARTY's QA must address publicly, not a defense.

-- citation --

botanical authentication question handled in food-science and aquaculture literature.

marty · by therma

THE BOTTOM LINE.

sea moss is the ingredient in MARTY's lineup with the weakest direct human RCT evidence. the reasonable use case is a mineral- and fiber-rich whole food with verified low heavy-metal and iodine load. specific clinical claims (libido, hair, thyroid) are not supported. people with thyroid disease, IBD, on anticoagulants, or pregnant should not use it.

apigenin

standardized extract, 50 mg

used in: marty-01

a flavone found in chamomile, parsley, and celery. MARTY 01 uses 50 mg/night, popularized in this dose by the Andrew Huberman "sleep cocktail" protocol.

it's also the ingredient with the loudest 'this is just a podcast supplement' critique. here are the five things people say about it.

“there are zero human RCTs of isolated 50 mg apigenin for sleep.”

WHAT’S RIGHT ABOUT IT.

fully correct as of April 2026. there is no published RCT testing isolated apigenin at 50 mg for sleep onset, maintenance, or quality. the sedative literature is animal (rodent) data and human trials of chamomile extract (which contains apigenin alongside dozens of other flavonoids and terpenes), not isolated apigenin. Rao G, Dou X (Antioxidants 2024) notes no human RCT has tested isolated 50 mg apigenin for sleep.

WHERE IT LANDS IN THE LITERATURE.

the mechanistic case is legitimate -- apigenin is a partial GABA-A agonist (Avallone R et al. Biochem Pharmacol 2000) and a CD38 inhibitor relevant to NAD+ biology (Escande C et al. Diabetes 2013). the closest human data is Zick SM et al. (BMC Complement Altern Med 2011; chamomile extract 270 mg, n=34, modest signal not reaching significance) and Mao JJ et al. (Phytomedicine 2016; chamomile 1,500 mg/day for GAD). the honest framing: the dose is mechanistically reasonable, well-tolerated, and supported by animal data, but the specific 50 mg human dose has not been formally validated.

-- citation --

Avallone R et al. Biochem Pharmacol 2000; 59(11): 1387-1394.

Zick SM et al. BMC Complement Altern Med 2011; 11: 78.

Mao JJ et al. Phytomedicine 2016; 23(14): 1735-1742.

marty · by therma

“the 50 mg apigenin dose was popularized by a podcast, not a clinical trial.”

WHAT’S RIGHT ABOUT IT.

reasonable epistemic critique. podcast-driven supplement adoption frequently outpaces published evidence. the 50 mg apigenin dose entered popular use through Huberman Lab episodes prior to any human sleep trial.

WHERE IT LANDS IN THE LITERATURE.

the criticism is about the messenger, not the molecule. apigenin's safety record is excellent, daily dietary intake from parsley/chamomile/celery already exceeds 50 mg in many populations, and no toxicity has been reported at supplement doses. the "Huberman backlash" is not a pharmacological refutation; it is a reasonable signal to wait for direct human data before claiming sleep efficacy.

-- citation --

no primary medical citation specific to media critique.

marty · by therma

“all the cancer/longevity claims are cell-culture or animal-only.”

WHAT’S RIGHT ABOUT IT.

conceded. the CD38 inhibition and NAD+-raising data are from rodents and cell lines (Escande 2013). anti-cancer claims rest on in vitro models without supportive human trials, including the one ClinicalTrials.gov apigenin/celery trial that was withdrawn (NCT03139227).

WHERE IT LANDS IN THE LITERATURE.

apigenin should be marketed as a calming/sleep flavonoid, not as a cancer or longevity agent. the latter would constitute structure-function claims unsupported by human data.

-- citation --

Escande C et al. Diabetes 2013; 62(4): 1084-1093.

marty · by therma

“apigenin inhibits CYP3A4 and P-gp -- drug interactions are real.”

WHAT’S RIGHT ABOUT IT.

mechanistically supported. Tang L et al. (Expert Opin Drug Metab Toxicol 2017) documented CYP3A4 and P-gp inhibition. Wang YC et al. (Molecules 2023) showed apigenin substantially altered dasatinib pharmacokinetics in rats. CYP3A4 metabolizes ~50% of all prescription drugs, including statins, calcium channel blockers, benzodiazepines, and many antidepressants.

WHERE IT LANDS IN THE LITERATURE.

the clinical relevance at 50 mg/day in humans is unestablished -- most interaction studies used much higher doses and extrapolation from rats overstates risk. anyone on a narrow-therapeutic-index drug (warfarin, tacrolimus, certain antiarrhythmics, tyrosine kinase inhibitors) should consult their prescriber before adding apigenin.

-- citation --

Tang L et al. Expert Opin Drug Metab Toxicol 2017; 13(3): 323-330.

Wang YC et al. Molecules 2023; 28(4): 1602.

marty · by therma

“you cannot isolate one flavonoid from chamomile and assume equivalence.”

WHAT’S RIGHT ABOUT IT.

defensible argument. chamomile extract contains apigenin alongside chamazulene, bisabolol, and other flavonoids. reductionist isolation of a single compound rarely replicates whole-extract pharmacology.

WHERE IT LANDS IN THE LITERATURE.

chamomile extract dose-equivalence: standard chamomile tea contains roughly 0.8-1.2% apigenin, meaning the 50 mg supplement dose corresponds to 8-15 cups of chamomile tea -- a magnitude justified by GABA-A binding affinity but not directly tested in humans against whole chamomile.

-- citation --

Srivastava JK, Shankar E, Gupta S. Mol Med Rep 2010; 3(6): 895-901.

marty · by therma

THE BOTTOM LINE.

apigenin at 50 mg has good safety, plausible mechanism, and zero direct human RCT evidence for sleep. it belongs in a sleep stack as a complement to better-evidenced ingredients (magnesium, glycine), not as the headline. the CYP3A4 interaction warning is real for narrow-therapeutic-index drugs.

l-theanine

Suntheanine, 100-200 mg

used in: marty-01, marty-03, marty-06, marty-07, marty-08

an amino acid from Camellia sinensis. the branded form Suntheanine has FDA GRAS status (GRN 209, 2007).

it's also the ingredient most often dismissed as 'just drink green tea.' here are the five things people say about it.

“just drink green tea.”

WHAT’S RIGHT ABOUT IT.

a typical cup of green tea contains 8-25 mg of L-theanine. to reach 200 mg, you would need 8-25 cups -- which would also load 800-2,500 mg of caffeine.

WHERE IT LANDS IN THE LITERATURE.

the point is precision dosing. green tea is fine but does not reliably deliver standardized theanine. Williams JL et al. (Plant Foods Hum Nutr 2020) catalogues the wide variation.

-- citation --

Williams JL et al. Plant Foods Hum Nutr 2020; 75(1): 12-23.

marty · by therma

“effect sizes in trials are weak and inconsistent.”

WHAT’S RIGHT ABOUT IT.

conceded. Sakamoto FL et al. (Pharmacol Res 2019; 5 RCTs, n=148) found promising but inconclusive effects on cognition. Williams JL et al. (2020) found inconsistent mood/anxiety findings. effect sizes are typically small (Hedges' g ~0.2-0.4) for cognition outcomes.

WHERE IT LANDS IN THE LITERATURE.

where effects are most reliable: combined with caffeine on attention/reaction time. the Nutrition Reviews 2024 systematic review of L-theanine + caffeine (50 RCTs, 15 in meta-analysis) found small-to-moderate effects on choice reaction time, attention switching accuracy, and mood (SMD 0.20-0.33). solo theanine effects are smaller and less reliable.

-- citation --

Sakamoto FL et al. Pharmacol Res 2019; 147: 104395.

Camfield DA et al. Nutr Rev 2014; 72(8): 507-522.

Nutrition Reviews 2024; 83(10): 1873.

marty · by therma

“FDA has not approved a structure-function claim for theanine.”

WHAT’S RIGHT ABOUT IT.

correct, but the framing is misleading. FDA does not approve structure-function claims for any supplement; manufacturers self-affirm them. what FDA did do is grant L-theanine (Suntheanine) GRAS status (GRN 209, 2007) at up to 250 mg per serving, after independent toxicology review.

WHERE IT LANDS IN THE LITERATURE.

GRAS status after toxicology review is the relevant safety benchmark, not structure-function claim approval (which does not exist as a regulatory process).

-- citation --

FDA GRAS Notice 209 (Suntheanine, Taiyo Kagaku, 2007).

marty · by therma

“long-term safety data is limited.”

WHAT’S RIGHT ABOUT IT.

conceded. most RCTs are 4-8 weeks. there is no published RCT >12 months. Borzelleca JF et al. (Food Chem Toxicol 2006) reported toxicology data from rats including a small uptick in renal tubule adenomas at 400 mg/kg/day in female rats.

WHERE IT LANDS IN THE LITERATURE.

no human safety signal has emerged in 30+ years of widespread use in beverages/foods in Japan or in clinical trials. the FDA GRAS evaluation considered chronic toxicology data. "limited long-term data" is true; "evidence of long-term harm" is not.

-- citation --

Borzelleca JF, Peters D, Hall W. Food Chem Toxicol 2006; 44(7): 1158-1166.

marty · by therma

“it only works combined with caffeine.”

WHAT’S RIGHT ABOUT IT.

effects are most reliable for cognition outcomes when paired with caffeine. Owen GN et al. (Nutr Neurosci 2008; n=27 crossover) showed the combination was the active condition for attention-switching tasks.

WHERE IT LANDS IN THE LITERATURE.

solo theanine has separate evidence for stress reduction and sleep quality, distinct from cognitive performance. Williams JL et al. (2020) note acute anxiolytic effects independent of caffeine; Dassanayake TL et al. (Hum Psychopharmacol 2022) found dose-dependent attention effects without caffeine. "only with caffeine" is false for stress and sleep endpoints; partially true for performance/cognition in healthy young adults.

-- citation --

Owen GN et al. Nutr Neurosci 2008; 11(4): 193-198.

marty · by therma

THE BOTTOM LINE.

L-theanine has FDA GRAS status, an excellent safety record, real but modest effects on stress/relaxation alone, and reliable synergy with caffeine for attention. the 100-200 mg dose is within the well-studied range.

glycine

USP-grade, 1,500 mg

used in: marty-01

a non-essential amino acid that functions both as an inhibitory neurotransmitter (glycine receptors) and an obligate co-agonist at NMDA receptors. MARTY 01 uses 1.5 g pre-bed.

it's also the ingredient where the dietary-vs-bolus argument actually matters. here are the five things people say about it.

“you already get plenty of glycine from food and collagen.”

WHAT’S RIGHT ABOUT IT.

true at the dietary level. endogenous synthesis is ~45 g/day (Gersovitz M et al. Am J Clin Nutr 1980), and dietary intake adds 3-5 g/day. collagen is ~33% glycine.

WHERE IT LANDS IN THE LITERATURE.

the relevant question is bolus pre-sleep delivery, not total daily intake. the Yamadera/Bannai/Inagawa Ajinomoto sleep trials all used a 3 g pre-bed bolus and found polysomnographic and subjective improvements not reproduced by dietary glycine. mechanism involves a hypothermic effect mediated by NMDA receptors in the suprachiasmatic nucleus (Kawai N et al. Neuropsychopharmacology 2015). 1.5 g is half the studied dose -- the rationale is co-administration with magnesium bisglycinate (which delivers another ~1 g of glycine equivalent).

-- citation --

Gersovitz M et al. Am J Clin Nutr 1980; 33(7): 1532-1538.

Kawai N et al. Neuropsychopharmacology 2015; 40(6): 1405-1416.

marty · by therma

“glycine is an NMDA co-agonist -- could be excitotoxic at the wrong dose.”

WHAT’S RIGHT ABOUT IT.

mechanistically real. glycine is an obligate co-agonist at the NMDA receptor's glycine-B site, and high-dose glycine has been used clinically to potentiate NMDA neurotransmission in schizophrenia trials at 0.4-0.8 g/kg/day (30-60 g/day for a 75 kg adult).

WHERE IT LANDS IN THE LITERATURE.

the schizophrenia dose is 20-40x the sleep dose. at 1.5-3 g pre-bed, glycine acts predominantly via inhibitory glycine receptors and SCN-mediated thermoregulation, not excitotoxic NMDA potentiation. Heresco-Levy U et al. (Arch Gen Psychiatry 1999; 0.8 g/kg/day) reported no excitotoxic adverse events even at psychiatric doses. the criticism conflates dose ranges by an order of magnitude.

-- citation --

Heresco-Levy U et al. Arch Gen Psychiatry 1999; 56(1): 29-36.

Javitt DC et al. Am J Psychiatry 1994; 151(8): 1234-1236.

marty · by therma

“the sleep evidence is thin and Japanese-only.”

WHAT’S RIGHT ABOUT IT.

honest concession. the primary RCT evidence is Inagawa K et al. (Sleep Biol Rhythms 2006; n=15); Yamadera W et al. (2007; n=11, polysomnography); Bannai M et al. (Front Neurol 2012; n=29). all are Japanese, all small, all funded by Ajinomoto, none independently replicated at scale outside Japan.

WHERE IT LANDS IN THE LITERATURE.

within their limitations, results were consistent: 3 g glycine pre-bed reduced subjective sleep latency, increased sleep efficiency, shortened polysomnographic latency to slow-wave sleep, and reduced next-day fatigue. the effect size is modest and the evidence base is open to replication critique. no safety signal in any trial.

-- citation --

Inagawa K et al. Sleep Biol Rhythms 2006; 4: 75-77.

Yamadera W et al. Sleep Biol Rhythms 2007; 5: 126-131.

Bannai M et al. Front Neurol 2012; 3: 61.

marty · by therma

“glycine interacts with clozapine.”

WHAT’S RIGHT ABOUT IT.

correct. glycine at supplemental doses can interfere with clozapine's efficacy. if you take clozapine, do not take this product.

WHERE IT LANDS IN THE LITERATURE.

this is a real contraindication and it is flagged on the product page. the criticism is right.

-- citation --

Evins AE et al. Am J Psychiatry 2000; 157(5): 826-828.

marty · by therma

“MARTY only uses 1,500 mg, not the studied 3,000 mg.”

WHAT’S RIGHT ABOUT IT.

correct. the most-cited glycine sleep trials use 3,000 mg. MARTY 01 uses 1,500 mg.

WHERE IT LANDS IN THE LITERATURE.

the choice is for pill burden. 3,000 mg of glycine alone would require 3+ additional capsules. at 1,500 mg combined with magnesium bisglycinate (which delivers ~1 g glycine equivalent), L-theanine, and apigenin, the stack works at 3 capsules total. the thermoregulatory effect is present at lower doses; the full 3 g dose may come in a future powder format.

-- citation --

Bannai M, Kawai N. J Pharmacol Sci 2012; 118(2): 145-148.

marty · by therma

THE BOTTOM LINE.

glycine at 1.5-3 g pre-bed has a real but small Japanese RCT base for sleep, no toxicity signal, and no NMDA-related safety concerns at this dose. the evidence is weaker than magnesium's; the safety profile is excellent.

methylated b-complex

5-MTHF, methylcobalamin, P5P, R5P

used in: marty-03, marty-09, marty-12

the active forms of folate, B12, B6, and B2. these bypass the methylation step that some bodies struggle with, especially those with MTHFR polymorphisms (estimated 30-40% of the general population).

it's also the ingredient where the regulator warnings are loudest. here are the five things people say about it.

“overmethylation is a real and underrecognized adverse effect -- anxiety, irritability, insomnia.”

WHAT’S RIGHT ABOUT IT.

clinically described, particularly in those with COMT polymorphisms or pre-existing anxiety. Mech AW, Farah A (J Clin Psychiatry 2016; n=502 antidepressant non-responders treated with 7.5 or 15 mg L-methylfolate) reported transient irritability/insomnia at higher dose. the mechanism -- pushing methylation pathways to elevated SAMe and downstream catecholamine synthesis -- is biologically real.

WHERE IT LANDS IN THE LITERATURE.

the 5-MTHF doses in MARTY (typically 400-1,000 mcg DFE) are an order of magnitude below the clinical psychiatric doses (7.5-15 mg) where overmethylation symptoms emerge. the underlying pharmacology of high-dose L-methylfolate is real; at RDA-level doses, the risk is low but individual variation exists.

-- citation --

Mech AW, Farah A. J Clin Psychiatry 2016; 77(5): 668-671.

Papakostas GI et al. Am J Psychiatry 2012; 169(12): 1267-1274.

marty · by therma

“MTHFR testing is overhyped pseudoscience.”

WHAT’S RIGHT ABOUT IT.

largely correct as practiced in wellness clinics. ACOG, ACMG, and the American Society of Hematology have all stated that MTHFR C677T/A1298C testing is not clinically indicated for most adult patients. ACMG Practice Guideline (Hickey SE et al. Genet Med 2013) explicitly recommends against routine MTHFR testing.

WHERE IT LANDS IN THE LITERATURE.

the MTHFR genotype is real and common (~10% of Europeans are homozygous TT), and homozygotes have measurably reduced enzymatic activity. Vidmar Golja M et al. (J Clin Med 2020) confirmed 5-MTHF supplementation bypasses the enzymatic block. do not get tested without indication, but if you are not converting folic acid efficiently, 5-MTHF is the form that works regardless of genotype.

-- citation --

Hickey SE et al. Genet Med 2013; 15(2): 153-156.

Vidmar Golja M et al. J Clin Med 2020; 9(9): 2836.

marty · by therma

“B6 toxicity from supplements is causing peripheral neuropathy -- TGA has flagged this.”

WHAT’S RIGHT ABOUT IT.

fully conceded -- this is a regulatory red flag. the Australian TGA has received hundreds of adverse-event reports of peripheral neuropathy from B6-containing supplements. the TGA has tightened B6 scheduling: oral preparations >50 mg/day will become pharmacist-only and >200 mg/day prescription-only effective June 1, 2027. Health Canada and New Zealand Medsafe have issued similar advisories. neuropathy can occur at doses as low as 10-50 mg/day with long-term use. Muhamad R et al. (Nutrients 2023) documented dose-time relationships.

WHERE IT LANDS IN THE LITERATURE.

MARTY's P5P doses are within a deliberately conservative range, formulated to total <10 mg pyridoxine-equivalent across all stacked SKUs. consumers stacking multiple supplements should sum their B6 across all products. P5P (the active coenzyme form) has been suggested to have a different toxicity profile than pyridoxine HCl, but this distinction is not yet established in human adverse-event data -- TGA scheduling treats all forms equivalently.

-- citation --

TGA Medicines Safety Update 2022 (peripheral neuropathy with B6).

TGA Final Decision on Vitamin B6 Scheduling, 2024 (effective June 1, 2027).

Muhamad R et al. Nutrients 2023; 15(13): 2823.

marty · by therma

“methylcobalamin is no better than cyanocobalamin -- it is just more expensive.”

WHAT’S RIGHT ABOUT IT.

substantially correct in healthy people. Paul C, Brady DM (Integr Med 2017) reviewed evidence and found minimal clinical difference in healthy adults; both forms ultimately enter the cellular cobalamin pool. some pharmacokinetic data even shows cyano- absorbed slightly better (49% vs. 44% at 1 mcg).

WHERE IT LANDS IN THE LITERATURE.

methylcobalamin shows higher tissue retention, lower urinary excretion, and may be preferable for patients with reduced hepatic conversion or specific cobalamin metabolism polymorphisms. differences are biochemically real and clinically minor in healthy individuals -- likely meaningful only in subpopulations (kidney disease, smokers, cobalamin metabolism disorders).

-- citation --

Paul C, Brady DM. Integr Med (Encinitas) 2017; 16(1): 42-49.

marty · by therma

“folic acid vs. folate confusion -- UMFA accumulation may have its own risks.”

WHAT’S RIGHT ABOUT IT.

real concern. unmetabolized folic acid (UMFA) accumulates in plasma at high folic acid intakes, particularly with the slow human DHFR enzymatic capacity (Bailey SW, Ayling JE. PNAS 2009). concerns include masked B12 deficiency and possible immune effects.

WHERE IT LANDS IN THE LITERATURE.

this is a genuine point in favor of methylated forms over folic acid. 5-MTHF supplementation does not generate UMFA. the folic acid vs. folate distinction is biochemically meaningful, even if marketing oversells it.

-- citation --

Bailey SW, Ayling JE. Proc Natl Acad Sci USA 2009; 106(36): 15424-15429.

marty · by therma

THE BOTTOM LINE.

methylated B-vitamins are reasonable in their active forms; 5-MTHF supports folate metabolism regardless of MTHFR status; B6 is the regulatory red flag -- keep total daily intake under 10 mg across all supplements and stop at any peripheral neuropathy symptoms.

rhodiola

SHR-5 extract, 400 mg/day

used in: marty-09

SHR-5 is the Swedish Herbal Institute's standardized Rhodiola rosea root extract (3% rosavins, 1% salidroside). used for stress-induced fatigue and burnout recovery.

it's also the ingredient where 'adaptogen' itself is contested. here are the five things people say about it.

“"adaptogen" is not a recognized pharmacological category.”

WHAT’S RIGHT ABOUT IT.

correct. "adaptogen" is a Soviet-era pharmacological concept without a defined receptor target, dose-response, or recognized regulatory category in FDA/EMA frameworks. EMA does have an herbal monograph for Rhodiola rosea (2012) with traditional-use indications, not well-established medicinal use.

WHERE IT LANDS IN THE LITERATURE.

"adaptogen" describes a phenotype (improves resistance to non-specific stressors) rather than a mechanism. the category is fuzzy; specific Rhodiola RCT outcomes are not.

-- citation --

EMA Committee on Herbal Medicinal Products. Community Herbal Monograph on Rhodiola rosea. EMA/HMPC/232091/2011, 2012.

marty · by therma

“RCT evidence is inconsistent and effects modest.”

WHAT’S RIGHT ABOUT IT.

Hung SK et al. (Phytomedicine 2011; 11 trials) found mixed methodological quality. Ishaque S et al. (BMC Complement Altern Med 2012) found unclear risk of bias. Mao JJ et al. (Phytomedicine 2015; the best US-based RCT, n=57, MDD, 12 weeks) found Rhodiola was not statistically superior to placebo, although it was better tolerated than sertraline.

WHERE IT LANDS IN THE LITERATURE.

modest, real effects on stress and fatigue; weaker, inconsistent effects on depression and cognition. Olsson EM et al. (Planta Med 2009; n=60, SHR-5 576 mg/day, stress-related fatigue) showed significant improvements in burnout and attention measures and cortisol awakening response. Spasov AA et al. (Phytomedicine 2000; n=56 physicians on night duty) found improved fatigue index. honest framing: real signal for stress-related fatigue, weak signal for major depression, well-tolerated.

-- citation --

Hung SK et al. Phytomedicine 2011; 18(4): 235-244.

Mao JJ et al. Phytomedicine 2015; 22(3): 394-399.

Olsson EM et al. Planta Med 2009; 75(2): 105-112.

marty · by therma

“rosavin/salidroside standardization varies wildly across products.”

WHAT’S RIGHT ABOUT IT.

correct and important. Booker A et al. (J Ethnopharmacol 2016) and the American Botanical Council's adulteration program have documented widespread Rhodiola adulteration, including substitution with Rhodiola crenulata and other species lacking rosavins.

WHERE IT LANDS IN THE LITERATURE.

branded standardized extracts (SHR-5 in particular) have HPLC-quantified rosavin and salidroside content. generic Rhodiola without standardization should not be assumed equivalent.

-- citation --

Booker A et al. J Ethnopharmacol 2016; 191: 27-37.

marty · by therma

“most fatigue trials are short (4 weeks or less).”

WHAT’S RIGHT ABOUT IT.

true. the mode trial duration is 14-28 days. long-term safety and efficacy data are sparse.

WHERE IT LANDS IN THE LITERATURE.

no specific signal for long-term harm; effect sizes were observed within 2-4 weeks. appropriate as a stress/fatigue intervention with periodic reassessment, not necessarily a permanent daily supplement.

-- citation --

Edwards D et al. Phytother Res 2012; 26(8): 1220-1225.

marty · by therma

“Soviet-era research cannot be taken at face value.”

WHAT’S RIGHT ABOUT IT.

reasonable epistemic concern. much of the foundational Rhodiola pharmacology is Russian/Soviet literature with limited methodological transparency by modern standards.

WHERE IT LANDS IN THE LITERATURE.

modern Western RCTs (Olsson 2009; Mao 2015; Edwards D et al. Phytother Res 2012 in chronic stress) have replicated parts of the older signal under more rigorous designs. the Soviet research motivated the modern work; it does not constitute the modern evidence base.

-- citation --

Edwards D, Heufelder A, Zimmermann A. Phytother Res 2012; 26(8): 1220-1225.

marty · by therma

THE BOTTOM LINE.

rhodiola SHR-5 at 400 mg has a modest, well-tolerated effect on stress-related fatigue and burnout. it is not an antidepressant. standardization matters; generic extracts should not be assumed equivalent.

lion's mane

fruiting body dual-extract 8:1, 1,500 mg

used in: marty-08

a culinary and medicinal mushroom used at 1,500 mg/day for cognitive/focus support. the credible form is dual-extract from the fruiting body, not mycelium-on-grain.

it's also the ingredient where the rumors run furthest ahead of the data. here are the five things people say about it.

“there is no human Alzheimer's data.”

WHAT’S RIGHT ABOUT IT.

conceded. the Mori K et al. (Phytotherapy Research 2009; n=30, ages 50-80, 16 weeks, 3 g/day fruiting body) trial was in mild cognitive impairment, not Alzheimer's, and effects waned 4 weeks after cessation. Saitsu Y et al. (Biomed Res 2019; n=31 healthy older adults, 12 weeks) showed cognitive improvement. there is no published Alzheimer's RCT in humans.

WHERE IT LANDS IN THE LITERATURE.

the Alzheimer's claims rest on rodent data with erinacine A-enriched mycelia (Li IC et al. Front Aging Neurosci 2020) and APP/PS1 mouse work. i do not make Alzheimer's claims. MARTY 08 is for cognitive support -- focus and clarity. the evidence supports "focus support," not "Alzheimer's prevention."

-- citation --

Mori K et al. Phytother Res 2009; 23(3): 367-372.

Saitsu Y et al. Biomed Res 2019; 40(4): 125-131.

Li IC et al. Front Aging Neurosci 2020; 12: 155.

marty · by therma

“NGF/BDNF claims are based on cell culture only.”

WHAT’S RIGHT ABOUT IT.

largely correct. Mori K et al. (Biol Pharm Bull 2008) demonstrated NGF induction in 1321N1 human astrocytoma cells. translation to humans is unestablished. hericenones cross blood-brain barrier in animal models but human pharmacokinetics are limited.

WHERE IT LANDS IN THE LITERATURE.

mechanism is plausible, human translation is unproven. the cognition signal in MCI/older adults exists independently of validated NGF mechanism in humans.

-- citation --

Mori K et al. Biol Pharm Bull 2008; 31(9): 1727-1732.

marty · by therma

“the testicular shrinkage rumor.”

WHAT’S RIGHT ABOUT IT.

this claim circulates widely on Reddit and TikTok.

WHERE IT LANDS IN THE LITERATURE.

there is no published case report or RCT showing lion's mane reduces testicular volume or testosterone in humans. the origin appears to be confused 5a-reductase inhibition speculation extrapolated from a single in-vitro paper, not human data. the rumor should be retired as supplement-internet folklore.

-- citation --

Mori K et al. Phytother Res 2009; 23(3): 367-372 (16-week RCT, no reproductive adverse events reported).

marty · by therma

“mushroom allergy is a real risk.”

WHAT’S RIGHT ABOUT IT.

documented. Kobernick A (Annals of Allergy, Asthma & Immunology 2022) reported the first published case of anaphylaxis to Hericium erinaceus in a 43-year-old man with positive fresh-food skin prick test, treated with epinephrine. cross-reactivity with other Basidiomycete fungi is plausible.

WHERE IT LANDS IN THE LITERATURE.

real but rare. people with known mushroom allergies should not take lion's mane.

-- citation --

Kobernick A et al. Ann Allergy Asthma Immunol 2022; 129(5S): S132.

marty · by therma

“fruiting body vs. mycelium-on-grain -- they are not equivalent and labeling is opaque.”

WHAT’S RIGHT ABOUT IT.

correct and important. fruiting body contains higher beta-glucan and hericenone content; mycelium-on-grain (the cheaper US default) is largely myceliated grain starch with low beta-glucan content. the American Herbal Pharmacopoeia and analytical work have documented the discrepancy. most positive trials used fruiting body powder.

WHERE IT LANDS IN THE LITERATURE.

this is a legitimate sourcing question answered with COA showing beta-glucan content (not "polysaccharide" content, which can include starch). this criticism is correct for the category -- not for this product.

-- citation --

Wu Y et al. J Food Sci 2021 (beta-glucan analytics in mushroom supplements).

marty · by therma

THE BOTTOM LINE.

lion's mane has a modest cognitive signal in MCI and older adults from small Japanese RCTs, plausible but unproven NGF mechanism in humans, very weak Alzheimer's claims, and a real but rare allergy risk. source matters: fruiting body with documented beta-glucan content is meaningfully different from generic mycelium-on-grain.

reishi

fruiting body dual-extract, 1,000 mg

used in: marty-11

Ganoderma lucidum, used at 1,000 mg/day for immune modulation. the only Cochrane-reviewed ingredient in this line (Jin X et al. 2016: "low to very low" quality evidence).

it's also the ingredient where the cochrane review came back equivocal. i'll say so. here are the five things people say about it.

“there is no high-quality clinical evidence in humans.”

WHAT’S RIGHT ABOUT IT.

largely conceded. Jin X et al. (Cochrane Database Syst Rev 2016; 5 RCTs, n=373, cancer) explicitly stated evidence quality was "low to very low" and concluded: "our review did not find sufficient evidence to justify the use of G. lucidum as a first-line treatment for cancer." trials were predominantly small Chinese RCTs with unclear randomization.

WHERE IT LANDS IN THE LITERATURE.

some evidence exists for adjunctive immune effects (NK cell activity, response rates with chemo/radiation: RR 1.50, 95% CI 0.90-2.51). for stress/sleep/general wellness, there is little RCT evidence. the defensible framing: traditional immunomodulator with low-quality clinical evidence; not a treatment.

-- citation --

Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Cochrane Database Syst Rev 2016; (4): CD007731.

marty · by therma

“reishi is a real bleeding risk with anticoagulants.”

WHAT’S RIGHT ABOUT IT.

conceded, with multiple case reports. Manno ML, Montinaro AM (La Rivista Italiana della Medicina di Laboratorio 2020) reported INR 6.92 and 8.22 in a hemodialysis patient on warfarin after taking 1,000 mg reishi. Memorial Sloan Kettering's herb-drug database explicitly lists reishi as risk for prolonging INR/PT/aPTT. doses >=3 g/day inhibit platelet aggregation.

WHERE IT LANDS IN THE LITERATURE.

clear contraindication: reishi + warfarin/DOACs/antiplatelets/scheduled surgery. MARTY 11's 1,000 mg dose is below the 3 g/day platelet-aggregation threshold but anyone on anticoagulants or facing surgery within 2 weeks should not use it.

-- citation --

Manno ML, Montinaro AM. Riv Ital Med Lab 2020; 16(4): 305-308.

Memorial Sloan Kettering Cancer Center. About Herbs: Reishi Mushroom (2024).

marty · by therma

“immune modulation is dangerous in autoimmune disease.”

WHAT’S RIGHT ABOUT IT.

theoretical concern. reishi increases NK and T-cell activity in laboratory and clinical assays. people on immunosuppressants for autoimmune disease or post-transplant should not take immunostimulants. MSKCC explicitly cautions against use with immunosuppressants.

WHERE IT LANDS IN THE LITERATURE.

no published case reports of disease flare from reishi in autoimmune disease, but the precautionary principle applies. contraindicated post-transplant and during immunosuppression.

-- citation --

Memorial Sloan Kettering Cancer Center About Herbs database (Reishi).

marty · by therma

“beta-glucan content varies enormously across products.”

WHAT’S RIGHT ABOUT IT.

correct. like lion's mane, reishi products vary enormously in actual beta-glucan content depending on extraction, hot water vs. dual extraction, fruiting body vs. mycelium. polysaccharide testing without specifically measuring beta-glucan can include starch and mask actual bioactive content.

WHERE IT LANDS IN THE LITERATURE.

sourcing transparency is the answer -- COA showing beta-glucan percentage and triterpene content.

-- citation --

analytical/quality question; no single primary citation.

marty · by therma

“reishi is just a wellness marketing term with no real benefit.”

WHAT’S RIGHT ABOUT IT.

"reishi" has been aggressively marketed by low-quality supplement brands with unsupported claims.

WHERE IT LANDS IN THE LITERATURE.

the beta-glucan immunomodulatory data is real and reproducible. the triterpene anti-inflammatory data is real. the cultural use spans thousands of years. the problem is marketing that overpromises, not the mushroom itself. but the Cochrane review's "low to very low" quality assessment means humility is warranted.

-- citation --

Jin X et al. Cochrane Database Syst Rev 2016; (4): CD007731.

marty · by therma

THE BOTTOM LINE.

reishi at 1,000 mg has weak human evidence (Cochrane: low-quality), a real anticoagulant interaction, and immune effects that contraindicate it in autoimmune disease and pre-surgery. use should be cautious and informed.

vitex (chasteberry)

standardized extract, 40 mg

used in: marty-05

Vitex agnus-castus dried fruit extract, used at 40 mg/day for cyclical mood and PMS-spectrum symptoms. the most-studied botanical for PMS comfort.

it's also the ingredient with the most legitimate medication-interaction concerns. here are the five things people say about it.

“vitex modulates prolactin via dopamine D2 -- drug-interaction risk is real.”

WHAT’S RIGHT ABOUT IT.

mechanism is well-established. Reinhardt JK et al. (Int J Mol Sci 2024) directly showed VAC diterpenes (viteagnusin I EC50 6.6 uM, rotundifuran EC50 12.8 uM) and triterpenes (3-epi-maslinic acid EC50 5.1 uM) activate D2 receptors. theoretical interactions with dopamine agonists/antagonists, antipsychotics, levodopa, and antiparkinsonian drugs are biologically plausible.

WHERE IT LANDS IN THE LITERATURE.

no published case reports of clinically significant interactions with antipsychotics or dopamine agonists. the precautionary disclosure: not for women on dopaminergic medications, antipsychotics, or with hyperprolactinemia from a pituitary tumor.

-- citation --

Reinhardt JK et al. Int J Mol Sci 2024; 25(21): 11456.

Wuttke W et al. Phytomedicine 2003; 10(4): 348-357.

marty · by therma

“hormone-sensitive condition warnings -- including breast cancer history.”

WHAT’S RIGHT ABOUT IT.

reasonable caution. vitex modulates prolactin, FSH, LH and shows weak estrogenic activity in some assays (Liu J et al. J Agric Food Chem 2001). patients with hormone-sensitive cancers, on tamoxifen/aromatase inhibitors, or with active endometriosis should not take vitex without oncology/endocrinology input.

WHERE IT LANDS IN THE LITERATURE.

standard contraindication labeled by EMA (HMPC monograph for Vitex agnus-castus) and most rational supplement formulators.

-- citation --

Liu J et al. J Agric Food Chem 2001; 49(5): 2472-2479.

EMA HMPC monograph: Vitex agnus-castus L. fructus 2018.

marty · by therma

“PMS meta-analyses are conflicting.”

WHAT’S RIGHT ABOUT IT.

honest concession. Verkaik S et al. (Am J Obstet Gynecol 2017; 8 RCTs, 1,392 women) found large pooled effect (RR 2.57) for PMS symptom remission but flagged "high risk of bias, high heterogeneity, and risk of publication bias." Cerqueira RO et al. (Arch Womens Ment Health 2017) was more skeptical.

WHERE IT LANDS IN THE LITERATURE.

when restricted to high-quality CONSORT-compliant trials of standardized extracts (Ze 440, BNO 1095), vitex outperforms placebo for PMS symptom reduction. cyclic mastalgia evidence (He Z et al. J Womens Health 2019; 25 studies, 17 RCTs) is more consistent.

-- citation --

Verkaik S et al. Am J Obstet Gynecol 2017; 217(2): 150-166.

Csupor D et al. Complement Ther Med 2019; 47: 102191.

He Z et al. J Womens Health 2019; 28(11): 1577-1585.

marty · by therma

“SSRI interaction is theoretical but worth disclosing.”

WHAT’S RIGHT ABOUT IT.

vitex's serotonergic activity is debated; Webster DE et al. (J Ethnopharmacol 2006) showed mu-opioid receptor activation for some VAC fractions. theoretical SSRI interaction is mostly speculative; no published case reports of serotonin syndrome from vitex + SSRI.

WHERE IT LANDS IN THE LITERATURE.

Atmaca M et al. (Hum Psychopharmacol 2003) directly compared vitex to fluoxetine in PMDD without interaction concerns. reasonable to caution against combining without prescriber awareness; not a hard contraindication.

-- citation --

Atmaca M et al. Hum Psychopharmacol 2003; 18(3): 191-195.

marty · by therma

“could affect hormonal contraception.”

WHAT’S RIGHT ABOUT IT.

theoretical concern. vitex modulates the HPO axis. Sexual Health Victoria (Australia) advises caution about possible interaction with hormonal contraception. there is no published RCT showing reduced contraceptive efficacy, but the LH/FSH/prolactin modulation creates plausible interference.

WHERE IT LANDS IN THE LITERATURE.

the MARTY 05 label discloses this. women relying on hormonal contraception for pregnancy prevention should consult their prescriber before adding vitex.

-- citation --

Sexual Health Victoria. Effect of Vitex agnus-castus on hormonal contraception. December 2020.

marty · by therma

THE BOTTOM LINE.

vitex at 40 mg of standardized extract has the strongest evidence for cyclic mastalgia and a real but heterogeneous signal for PMS. hormone-sensitive disease, dopaminergic medications, and hormonal contraception are all reasons to consult a clinician first.

psychobiotics (Cerebiome)

L. helveticus R0052 + B. longum R0175, 3 billion CFU

used in: marty-06

the R0052/R0175 combination (commercially Cerebiome/Probio'Stick) is one of the few probiotic strain combinations with strain-specific RCT data for mood.

it's also the ingredient where strain specificity matters more than the marketing usually admits. here are the five things people say about it.

“probiotics do not survive stomach acid.”

WHAT’S RIGHT ABOUT IT.

strain-dependent and partially correct. acid and bile tolerance vary enormously between strains. a 2014 University College London study tested 8 commercial probiotics and found only one survived gastric acidity. Bifidobacterium species are particularly acid-sensitive.

WHERE IT LANDS IN THE LITERATURE.

R0052 and R0175 specifically have been characterized for acid/bile tolerance and gastrointestinal survival in vitro and in vivo. Cerebiome is delivered with strain-specific encapsulation designed for gastric protection. the blanket "probiotics do not survive stomach acid" claim is true for some strains, demonstrably false for these. effect on the gut-brain axis may also occur via vagal signaling and metabolite production, not requiring full colonization.

-- citation --

Foster LM, Tompkins TA, Dahl WJ. Benef Microbes 2011; 2(4): 319-334.

marty · by therma

“strain specificity claims are not matched by other generic probiotic products.”

WHAT’S RIGHT ABOUT IT.

correct as a critique of the broader probiotic industry. generic "probiotics" extrapolating from R0052/R0175 trials is unjustified.

WHERE IT LANDS IN THE LITERATURE.

this is precisely why MARTY 06 names the strains. Messaoudi M et al. (British Journal of Nutrition 2011; n=55 healthy adults, 30 days) found significant reductions in HSCL-90 global severity (p<0.05), depression sub-score (p<0.05), HADS anxiety (p<0.06), and 24-hour urinary free cortisol (p<0.05). the strain pair, not "probiotics" generically, is the claim.

-- citation --

Messaoudi M et al. Br J Nutr 2011; 105(5): 755-764.

Messaoudi M et al. Gut Microbes 2011; 2(4): 256-261.

marty · by therma

“probiotics-for-mood meta-analyses are mixed.”

WHAT’S RIGHT ABOUT IT.

conceded. Ng QX et al. (J Affect Disord 2018; 10 RCTs, n=1,349) found no significant overall effect on mood (SMD -0.128, p=0.059). Nikolova VL et al. (Ther Adv Psychopharmacol 2019) found probiotics effective only as adjuncts to antidepressants (SMD 0.83), not as standalone (SMD -0.02).

WHERE IT LANDS IN THE LITERATURE.

meta-analyses pool heterogeneous strains, doses, and populations -- which obscures strain-specific signal. the R0052/R0175 strain-specific evidence is more positive than the generic-probiotic pool. Kazemi A et al. (Clin Nutr 2019; MDD) with similar L. helveticus + Bifidobacterium combination showed benefit. effect sizes are modest (SMD ~0.3) and most meaningful in adjunctive use.

-- citation --

Ng QX et al. J Affect Disord 2018; 228: 13-19.

Nikolova VL et al. Ther Adv Psychopharmacol 2019; 9.

Kazemi A et al. Clin Nutr 2019; 38(2): 522-528.

marty · by therma

“CFU count is meaningless if cells are not viable at end of shelf life.”

WHAT’S RIGHT ABOUT IT.

real concern. CFU count at manufacture is not CFU count at expiration. many products lose >50% viability over 12 months at room temperature. the IPA recommends end-of-shelf-life CFU labeling, which most products do not provide.

WHERE IT LANDS IN THE LITERATURE.

Cerebiome strains (Lallemand) ship with CFU specifications maintained through expiration. honest products label "X billion CFU at expiration" rather than "at manufacture."

-- citation --

International Probiotics Association labeling guidance, 2017.

marty · by therma

“the placebo response in mood trials is enormous.”

WHAT’S RIGHT ABOUT IT.

true for almost all mood interventions. placebo response in depression RCTs averages 30-40%, and probiotic trials are not exempt.

WHERE IT LANDS IN THE LITERATURE.

this is a structural issue with mood-trial methodology, not probiotic-specific. the Messaoudi trials used proper double-blind placebo control, and effect sizes were modest but statistically robust on multiple validated scales (HSCL-90, HADS, urinary cortisol).

-- citation --

Messaoudi M et al. Br J Nutr 2011; 105(5): 755-764.

marty · by therma

THE BOTTOM LINE.

L. helveticus R0052 + B. longum R0175 at 3 billion CFU is one of the few probiotic combinations with strain-specific human RCT data for mood. effect is modest, real, and most reliable as adjunctive support rather than monotherapy. people who are immunocompromised, post-transplant, or with central venous catheters should consult their physician.

THE LEGAL PART.

these statements have not been evaluated by the FDA. these products are not intended to diagnose, treat, cure, or prevent any disease.

the studies cited on this page were measuring specific outcomes in specific populations at specific doses. they don't make a supplement a treatment. if you have a diagnosed condition, see a doctor -- not me.

last updated: 2026-04-29